Literature DB >> 30798982

Agreement of CK5/6, p40, and p63 immunoreactivity in non-small cell lung cancer.

Katharina Kriegsmann1, Martin Cremer1, Christiane Zgorzelski2, Alexander Harms3, Thomas Muley4, Hauke Winter5, Daniel Kazdal3, Arne Warth6, Mark Kriegsmann7.   

Abstract

Histological subtyping of non-small cell lung cancer (NSCLC) is of utmost importance for therapy stratification. Common immunohistochemical markers to identify squamous lineage are CK5/6, p40, and p63. Although p40 is considered the gold standard by current guidelines, the agreement of all three markers is an important aspect for tumours more difficult to classify. A total of 1244 NSCLC including 569 squamous cell carcinomas (SqCC) and 675 adenocarcinomas were assembled on a tissue microarray and stained with CK5/6, p40, p63, TTF-1, and Napsin-A. Sensitivity and specificity for squamous lineage markers as well as agreement of CK5/6, p40 and p63 were calculated. Sensitivity of CK5/6, p40, and p63 for SqCC was 93%, 94%, and 94% and specificity was 98%, 97%, and 84%, respectively. Positivity for two of these markers was found in at least in 90% of SqCC. Highest agreement was observed for p40 and p63 (Cohen's kappa 0.80). We report a similar sensitivity of CK5/6, p40, and p63, but a decreased specificity of p63 as compared to CK5/6 and p40 for the identification of squamous lineage. Our results support the use of either CK5/6 or p40 over p63 in the routine diagnostic setting.
Copyright © 2019 Royal College of Pathologists of Australasia. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  CK5/6; NSCLC; lung cancer; p40; p63

Mesh:

Substances:

Year:  2019        PMID: 30798982     DOI: 10.1016/j.pathol.2018.11.009

Source DB:  PubMed          Journal:  Pathology        ISSN: 0031-3025            Impact factor:   5.306


  13 in total

1.  2020 Innovation-Based Optimism for Lung Cancer Outcomes.

Authors:  Erin L Schenk; Tejas Patil; Jose Pacheco; Paul A Bunn
Journal:  Oncologist       Date:  2020-12-20

2.  LINC00173.v1 promotes angiogenesis and progression of lung squamous cell carcinoma by sponging miR-511-5p to regulate VEGFA expression.

Authors:  Jiarong Chen; Aibin Liu; Zhihui Wang; Bin Wang; Xingxing Chai; Wenjie Lu; Ting Cao; Ronggang Li; Minyan Wu; Zhuming Lu; Wenguang Pang; Lin Xiao; Xiangmeng Chen; Yan Zheng; Qiong Chen; Jincheng Zeng; Jun Li; Xin Zhang; Dong Ren; Yanming Huang
Journal:  Mol Cancer       Date:  2020-05-30       Impact factor: 27.401

3.  Role of downregulated ADARB1 in lung squamous cell carcinoma.

Authors:  Xiang Wang; Xinxin Ren; Wanli Liu; Xi Chen; Jie Wei; Zhicheng Gong; Yuanliang Yan; Zhijie Xu
Journal:  Mol Med Rep       Date:  2020-01-23       Impact factor: 2.952

Review 4.  p63 Is a Promising Marker in the Diagnosis of Unusual Skin Cancer.

Authors:  Artem Smirnov; Lucia Anemona; Flavia Novelli; Cristina M Piro; Margherita Annicchiarico-Petruzzelli; Gerry Melino; Eleonora Candi
Journal:  Int J Mol Sci       Date:  2019-11-17       Impact factor: 5.923

5.  Glypican-1 is a novel immunohistochemical marker to differentiate poorly differentiated squamous cell carcinoma from solid predominant adenocarcinoma of the lung.

Authors:  Yuichiro Kai; Vishwa Jeet Amatya; Kei Kushitani; Takahiro Kambara; Rui Suzuki; Yutaro Fujii; Yasuhiro Tsutani; Yoshihiro Miyata; Morihito Okada; Yukio Takeshima
Journal:  Transl Lung Cancer Res       Date:  2021-02

6.  Role of Synaptophysin, Chromogranin and CD56 in adenocarcinoma and squamous cell carcinoma of the lung lacking morphological features of neuroendocrine differentiation: a retrospective large-scale study on 1170 tissue samples.

Authors:  Katharina Kriegsmann; Christiane Zgorzelski; Thomas Muley; Petros Christopoulos; Michael Thomas; Hauke Winter; Martin Eichhorn; Florian Eichhorn; Moritz von Winterfeld; Esther Herpel; Benjamin Goeppert; Albrecht Stenzinger; Felix J F Herth; Arne Warth; Mark Kriegsmann
Journal:  BMC Cancer       Date:  2021-05-01       Impact factor: 4.430

7.  SOX10 - A Novel Marker for the Differential Diagnosis of Breast Metaplastic Squamous Cell Carcinoma.

Authors:  Jialin Qi; Zhenmin Hu; Heng Xiao; Ruijie Liu; Wei Guo; Zhichun Yang; Kewen Ma; Shitong Su; Ping Tang; Xunjian Zhou; Jianhua Zhou; Kuansong Wang
Journal:  Cancer Manag Res       Date:  2020-05-28       Impact factor: 3.989

8.  Use of dual-marker staining to differentiate between lung squamous cell carcinoma and adenocarcinoma.

Authors:  Rui Guo; Yi Tian; Na Zhang; Hong Huang; Ying Huang; Jun Yang
Journal:  J Int Med Res       Date:  2019-12-27       Impact factor: 1.671

9.  A Case of Pulmonary Embolism with Sarcomatoid Malignant Pleural Mesothelioma with Long-Term Pleural Effusion.

Authors:  Rumeng Gu; Luxi Jiang; Ting Duan; Chun Chen; Shengchang Wu; Deguang Mu
Journal:  Onco Targets Ther       Date:  2021-07-16       Impact factor: 4.147

10.  Napsin A Expression in Human Tumors and Normal Tissues.

Authors:  Sören Weidemann; Jan Lukas Böhle; Hendrina Contreras; Andreas M Luebke; Martina Kluth; Franziska Büscheck; Claudia Hube-Magg; Doris Höflmayer; Katharina Möller; Christoph Fraune; Christian Bernreuther; Michael Rink; Ronald Simon; Anne Menz; Andrea Hinsch; Patrick Lebok; Till Clauditz; Guido Sauter; Ria Uhlig; Waldemar Wilczak; Stefan Steurer; Eike Burandt; Rainer Krech; David Dum; Till Krech; Andreas Marx; Sarah Minner
Journal:  Pathol Oncol Res       Date:  2021-04-20       Impact factor: 3.201

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.